|
20 Oct 2020 |
Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
|
|
20 Oct 2020 |
Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
|
|
20 Oct 2020 |
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
|
|
20 Oct 2020 |
Tagrisso granted Priority Review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
|
|
19 Oct 2020 |
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis
|
|
19 Oct 2020 |
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
|
|
19 Oct 2020 |
Cocrystal Pharma Provides Update on Influenza A Program
|
|
19 Oct 2020 |
Forxiga recommended for approval in the EU by CHMP for heart failure
|
|
19 Oct 2020 |
Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD
|
|
17 Oct 2020 |
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
|
|
17 Oct 2020 |
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
|
|
17 Oct 2020 |
Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
|
|
16 Oct 2020 |
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
|
|
16 Oct 2020 |
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
|
|
16 Oct 2020 |
Astex and Otsuka Announce Results of Phase 3 ASTRAL-2 and ASTRAL-3 Studies of Guadecitabine (SGI-110) in Patients with Previously Treated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (MDS/CMML)
|
|
16 Oct 2020 |
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
|
|
16 Oct 2020 |
Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD
|
|
16 Oct 2020 |
Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis
|
|
16 Oct 2020 |
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
|
|
15 Oct 2020 |
GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy
|
|
15 Oct 2020 |
Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
|
|
14 Oct 2020 |
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
|
|
14 Oct 2020 |
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
|
|
14 Oct 2020 |
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
|
|
14 Oct 2020 |
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
|
